The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Once-daily aminoglycoside therapy
Open accessAbstract
The once-daily administration of aminoglycosides is an attractive concept. In animal experiments and clinical trials, there is either a reduction in or no influence on the risk of toxicity. Less frequent dosing reduces the contact time between host tissue binding sites and drug. Thanks to the PAE and perhaps other as-yet-unrecognized factors, the fall in the level in serum below the MIC does not appear to impair antibacterial efficacy; in fact, the higher peak level in serum may enhance drug efficacy early in a dosage interval. In neutropenic patients, the in vivo PAE may be lost or small-colony variants with a shorter PAE may be selected unless a concomitant beta-lactam is administered. Because it will be some time before data from clinical trials in the United States are available, because the results from the international trials are encouraging, and because there is potential benefit to patients, it seems reasonable for infectious diseases consultants to cautiously initiate the educational process necessary to implement once-daily aminoglycoside therapy in their institutions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Mechanism of bactericidal action of aminoglycosides
Davis, B. D. (1987) · Microbiological Reviews · doi:10.1128/mmbr.51.3.341-350.1987 · Cited by 620
Moore, R. D., Smith, C. R., & Lietman, P. S. (1984) · Journal of Infectious Diseases · doi:10.1093/infdis/149.3.443 · Cited by 390
Experience in Monitoring Gentamicin Therapy during Treatment of Serious Gram-Negative Sepsis
Noone, P., Parsons, T. M. C., Pattison, J. R., Slack, R. C. B., Garfield-Davies, D., & Hughes, K. (1974) · BMJ · doi:10.1136/bmj.1.5906.477 · Cited by 347
Role of pharmacokinetics in the outcome of infections
Drusano, G. L. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.3.289 · Cited by 330
Kinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315
Postantibiotic Suppression of Bacterial Growth
Bundtzen, R. W., Gerber, A. U., Cohn, D. L., & Craig, W. A. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.28 · Cited by 311
Powell, S. H., Thompson, W. L., Luthe, M. A., Stern, R. C., Grossniklaus, D. A., Bloxham, D. D., Groden, D. L., Jacobs, M. R., DiScenna, A. O., Cash, H. A., et al. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.918 · Cited by 272
In Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic Mice
Vogelman, B., Gudmundsson, S., Turnidge, J., Leggett, J., & Craig, W. A. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.2.287 · Cited by 259
Cited by
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Versatility of Aminoglycosides and Prospects for Their Future
Vakulenko, S. B., & Mobashery, S. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.3.430-450.2003 · Cited by 643
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
Nicolau, D. P., Freeman, C. D., Belliveau, P. P., Nightingale, C. H., Ross, J. W., & Quintiliani, R. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.650 · Cited by 641
Single or multiple daily doses of aminoglycosides: a meta-analysis
Barza, M., Ioannidis, J. P., Cappelleri, J. C., & Lau, J. (1996) · BMJ · doi:10.1136/bmj.312.7027.338 · Cited by 450
Rybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., & Drusano, G. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1549 · Cited by 431
A suggested approach to once‐daily aminoglycoside dosing.
Begg, E., Barclay, M., & Duffull, S. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05719.x · Cited by 420
Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update
Keane, W. F., Bailie, G. R., Boeschoten, E., Gokal, R., Golper, T. A., Holmes, C. J., Kawaguchi, Y., Piraino, B., Riella, M., & Vas, S. (2000) · Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · doi:10.1177/089686080002000406 · Cited by 410
Once versus thrice daily gentamicin in patients with serious infections
Prins, J. M., Buller, H. R., Speelman, P., Kuijper, E. J., & Tange, R. A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90137-6 · Cited by 350
Drug-induced acute kidney injury
Schetz, M., Dasta, J., Goldstein, S., & Golper, T. (2005) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000184300.68383.95 · Cited by 313
Roberts, J. A., & Lipman, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645080-00001 · Cited by 283
Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases
Peloquin, C. A., Berning, S. E., Nitta, A. T., Simone, P. M., Goble, M., Huitt, G. A., Iseman, M. D., Cook, J. L., & Curran-Everett, D. (2004) · Clinical Infectious Diseases · doi:10.1086/420742 · Cited by 270
The importance of residual renal function in dialysis patients
Wang, A. Y.-M., & Lai, K.-N. (2006) · Kidney International · doi:10.1038/sj.ki.5000382 · Cited by 257
Pharmacological Issues in the Treatment of Tuberculosis
PELOQUIN, C. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb11374.x · Cited by 82
Cremieux, A. C., Saleh-Mghir, A., Vallois, J. M., Maziere, B., Muffat-Joly, M., Devine, C., Bouvet, A., Pocidalo, J. J., & Carbon, C. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.10.2216 · Cited by 18
Metadata
- Authors
- Gilbert, D. N.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1991-03
- Volume
- 35
- Issue
- 3
- Pages
- 399-405
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2114422486
- Cited by
- 324
- References
- 40
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.